Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study
HERmione study was conducted to assess, in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC), the safety profile of subcutaneous (SC) formulation of trastuzumab in real-life in France.
Gespeichert in:
| Autor*in: |
Jacquin, Jean-Philippe [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2020 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
7 |
|---|
| Übergeordnetes Werk: |
Enthalten in: The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study - Yang, Lin ELSEVIER, 2020, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:49 ; year:2020 ; pages:1-7 ; extent:7 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.breast.2019.10.002 |
|---|
| Katalog-ID: |
ELV049299751 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV049299751 | ||
| 003 | DE-627 | ||
| 005 | 20230624153350.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200518s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.breast.2019.10.002 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001071.pica |
| 035 | |a (DE-627)ELV049299751 | ||
| 035 | |a (ELSEVIER)S0960-9776(19)30565-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.65 |2 bkl | ||
| 100 | 1 | |a Jacquin, Jean-Philippe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study |
| 264 | 1 | |c 2020 | |
| 300 | |a 7 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a HERmione study was conducted to assess, in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC), the safety profile of subcutaneous (SC) formulation of trastuzumab in real-life in France. | ||
| 650 | 7 | |a HER2-Positive |2 Elsevier | |
| 650 | 7 | |a SC |2 Elsevier | |
| 650 | 7 | |a Prospective non-interventional study |2 Elsevier | |
| 650 | 7 | |a Early breast cancer |2 Elsevier | |
| 650 | 7 | |a Trastuzumab |2 Elsevier | |
| 650 | 7 | |a Sub-cutaneous injection |2 Elsevier | |
| 650 | 7 | |a Safety profile |2 Elsevier | |
| 700 | 1 | |a Uwer, Lionel |4 oth | |
| 700 | 1 | |a Savignoni, Alexia |4 oth | |
| 700 | 1 | |a Ferrero, Jean-Marc |4 oth | |
| 700 | 1 | |a Lortholary, Alain |4 oth | |
| 700 | 1 | |a Solub, David |4 oth | |
| 700 | 1 | |a Delaporte, Flore |4 oth | |
| 700 | 1 | |a Chalabi, Nassera |4 oth | |
| 700 | 1 | |a Pibre, Sophie |4 oth | |
| 700 | 1 | |a Belkacemi, Yazid |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Yang, Lin ELSEVIER |t The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study |d 2020 |g Amsterdam [u.a.] |w (DE-627)ELV004843835 |
| 773 | 1 | 8 | |g volume:49 |g year:2020 |g pages:1-7 |g extent:7 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.breast.2019.10.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.65 |j Chirurgie |q VZ |
| 951 | |a AR | ||
| 952 | |d 49 |j 2020 |h 1-7 |g 7 | ||
| author_variant |
j p j jpj |
|---|---|
| matchkey_str |
jacquinjeanphilippeuwerlionelsavignonial:2020----:aeyrflosbuaeutatzmbnainsihe2oiiealbescneternhemo |
| hierarchy_sort_str |
2020 |
| bklnumber |
44.65 |
| publishDate |
2020 |
| allfields |
10.1016/j.breast.2019.10.002 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001071.pica (DE-627)ELV049299751 (ELSEVIER)S0960-9776(19)30565-X DE-627 ger DE-627 rakwb eng 610 VZ 44.65 bkl Jacquin, Jean-Philippe verfasserin aut Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study 2020 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier HERmione study was conducted to assess, in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC), the safety profile of subcutaneous (SC) formulation of trastuzumab in real-life in France. HER2-Positive Elsevier SC Elsevier Prospective non-interventional study Elsevier Early breast cancer Elsevier Trastuzumab Elsevier Sub-cutaneous injection Elsevier Safety profile Elsevier Uwer, Lionel oth Savignoni, Alexia oth Ferrero, Jean-Marc oth Lortholary, Alain oth Solub, David oth Delaporte, Flore oth Chalabi, Nassera oth Pibre, Sophie oth Belkacemi, Yazid oth Enthalten in Elsevier Yang, Lin ELSEVIER The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study 2020 Amsterdam [u.a.] (DE-627)ELV004843835 volume:49 year:2020 pages:1-7 extent:7 https://doi.org/10.1016/j.breast.2019.10.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.65 Chirurgie VZ AR 49 2020 1-7 7 |
| spelling |
10.1016/j.breast.2019.10.002 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001071.pica (DE-627)ELV049299751 (ELSEVIER)S0960-9776(19)30565-X DE-627 ger DE-627 rakwb eng 610 VZ 44.65 bkl Jacquin, Jean-Philippe verfasserin aut Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study 2020 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier HERmione study was conducted to assess, in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC), the safety profile of subcutaneous (SC) formulation of trastuzumab in real-life in France. HER2-Positive Elsevier SC Elsevier Prospective non-interventional study Elsevier Early breast cancer Elsevier Trastuzumab Elsevier Sub-cutaneous injection Elsevier Safety profile Elsevier Uwer, Lionel oth Savignoni, Alexia oth Ferrero, Jean-Marc oth Lortholary, Alain oth Solub, David oth Delaporte, Flore oth Chalabi, Nassera oth Pibre, Sophie oth Belkacemi, Yazid oth Enthalten in Elsevier Yang, Lin ELSEVIER The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study 2020 Amsterdam [u.a.] (DE-627)ELV004843835 volume:49 year:2020 pages:1-7 extent:7 https://doi.org/10.1016/j.breast.2019.10.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.65 Chirurgie VZ AR 49 2020 1-7 7 |
| allfields_unstemmed |
10.1016/j.breast.2019.10.002 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001071.pica (DE-627)ELV049299751 (ELSEVIER)S0960-9776(19)30565-X DE-627 ger DE-627 rakwb eng 610 VZ 44.65 bkl Jacquin, Jean-Philippe verfasserin aut Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study 2020 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier HERmione study was conducted to assess, in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC), the safety profile of subcutaneous (SC) formulation of trastuzumab in real-life in France. HER2-Positive Elsevier SC Elsevier Prospective non-interventional study Elsevier Early breast cancer Elsevier Trastuzumab Elsevier Sub-cutaneous injection Elsevier Safety profile Elsevier Uwer, Lionel oth Savignoni, Alexia oth Ferrero, Jean-Marc oth Lortholary, Alain oth Solub, David oth Delaporte, Flore oth Chalabi, Nassera oth Pibre, Sophie oth Belkacemi, Yazid oth Enthalten in Elsevier Yang, Lin ELSEVIER The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study 2020 Amsterdam [u.a.] (DE-627)ELV004843835 volume:49 year:2020 pages:1-7 extent:7 https://doi.org/10.1016/j.breast.2019.10.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.65 Chirurgie VZ AR 49 2020 1-7 7 |
| allfieldsGer |
10.1016/j.breast.2019.10.002 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001071.pica (DE-627)ELV049299751 (ELSEVIER)S0960-9776(19)30565-X DE-627 ger DE-627 rakwb eng 610 VZ 44.65 bkl Jacquin, Jean-Philippe verfasserin aut Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study 2020 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier HERmione study was conducted to assess, in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC), the safety profile of subcutaneous (SC) formulation of trastuzumab in real-life in France. HER2-Positive Elsevier SC Elsevier Prospective non-interventional study Elsevier Early breast cancer Elsevier Trastuzumab Elsevier Sub-cutaneous injection Elsevier Safety profile Elsevier Uwer, Lionel oth Savignoni, Alexia oth Ferrero, Jean-Marc oth Lortholary, Alain oth Solub, David oth Delaporte, Flore oth Chalabi, Nassera oth Pibre, Sophie oth Belkacemi, Yazid oth Enthalten in Elsevier Yang, Lin ELSEVIER The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study 2020 Amsterdam [u.a.] (DE-627)ELV004843835 volume:49 year:2020 pages:1-7 extent:7 https://doi.org/10.1016/j.breast.2019.10.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.65 Chirurgie VZ AR 49 2020 1-7 7 |
| allfieldsSound |
10.1016/j.breast.2019.10.002 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001071.pica (DE-627)ELV049299751 (ELSEVIER)S0960-9776(19)30565-X DE-627 ger DE-627 rakwb eng 610 VZ 44.65 bkl Jacquin, Jean-Philippe verfasserin aut Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study 2020 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier HERmione study was conducted to assess, in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC), the safety profile of subcutaneous (SC) formulation of trastuzumab in real-life in France. HER2-Positive Elsevier SC Elsevier Prospective non-interventional study Elsevier Early breast cancer Elsevier Trastuzumab Elsevier Sub-cutaneous injection Elsevier Safety profile Elsevier Uwer, Lionel oth Savignoni, Alexia oth Ferrero, Jean-Marc oth Lortholary, Alain oth Solub, David oth Delaporte, Flore oth Chalabi, Nassera oth Pibre, Sophie oth Belkacemi, Yazid oth Enthalten in Elsevier Yang, Lin ELSEVIER The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study 2020 Amsterdam [u.a.] (DE-627)ELV004843835 volume:49 year:2020 pages:1-7 extent:7 https://doi.org/10.1016/j.breast.2019.10.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.65 Chirurgie VZ AR 49 2020 1-7 7 |
| language |
English |
| source |
Enthalten in The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study Amsterdam [u.a.] volume:49 year:2020 pages:1-7 extent:7 |
| sourceStr |
Enthalten in The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study Amsterdam [u.a.] volume:49 year:2020 pages:1-7 extent:7 |
| format_phy_str_mv |
Article |
| bklname |
Chirurgie |
| institution |
findex.gbv.de |
| topic_facet |
HER2-Positive SC Prospective non-interventional study Early breast cancer Trastuzumab Sub-cutaneous injection Safety profile |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study |
| authorswithroles_txt_mv |
Jacquin, Jean-Philippe @@aut@@ Uwer, Lionel @@oth@@ Savignoni, Alexia @@oth@@ Ferrero, Jean-Marc @@oth@@ Lortholary, Alain @@oth@@ Solub, David @@oth@@ Delaporte, Flore @@oth@@ Chalabi, Nassera @@oth@@ Pibre, Sophie @@oth@@ Belkacemi, Yazid @@oth@@ |
| publishDateDaySort_date |
2020-01-01T00:00:00Z |
| hierarchy_top_id |
ELV004843835 |
| dewey-sort |
3610 |
| id |
ELV049299751 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV049299751</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624153350.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200518s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.breast.2019.10.002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001071.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV049299751</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0960-9776(19)30565-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.65</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Jacquin, Jean-Philippe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">HERmione study was conducted to assess, in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC), the safety profile of subcutaneous (SC) formulation of trastuzumab in real-life in France.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HER2-Positive</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Prospective non-interventional study</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Early breast cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Trastuzumab</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sub-cutaneous injection</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Safety profile</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Uwer, Lionel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Savignoni, Alexia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ferrero, Jean-Marc</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lortholary, Alain</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Solub, David</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Delaporte, Flore</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chalabi, Nassera</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pibre, Sophie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Belkacemi, Yazid</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Yang, Lin ELSEVIER</subfield><subfield code="t">The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study</subfield><subfield code="d">2020</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV004843835</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:49</subfield><subfield code="g">year:2020</subfield><subfield code="g">pages:1-7</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.breast.2019.10.002</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.65</subfield><subfield code="j">Chirurgie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">49</subfield><subfield code="j">2020</subfield><subfield code="h">1-7</subfield><subfield code="g">7</subfield></datafield></record></collection>
|
| author |
Jacquin, Jean-Philippe |
| spellingShingle |
Jacquin, Jean-Philippe ddc 610 bkl 44.65 Elsevier HER2-Positive Elsevier SC Elsevier Prospective non-interventional study Elsevier Early breast cancer Elsevier Trastuzumab Elsevier Sub-cutaneous injection Elsevier Safety profile Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study |
| authorStr |
Jacquin, Jean-Philippe |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV004843835 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 44.65 bkl Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study HER2-Positive Elsevier SC Elsevier Prospective non-interventional study Elsevier Early breast cancer Elsevier Trastuzumab Elsevier Sub-cutaneous injection Elsevier Safety profile Elsevier |
| topic |
ddc 610 bkl 44.65 Elsevier HER2-Positive Elsevier SC Elsevier Prospective non-interventional study Elsevier Early breast cancer Elsevier Trastuzumab Elsevier Sub-cutaneous injection Elsevier Safety profile |
| topic_unstemmed |
ddc 610 bkl 44.65 Elsevier HER2-Positive Elsevier SC Elsevier Prospective non-interventional study Elsevier Early breast cancer Elsevier Trastuzumab Elsevier Sub-cutaneous injection Elsevier Safety profile |
| topic_browse |
ddc 610 bkl 44.65 Elsevier HER2-Positive Elsevier SC Elsevier Prospective non-interventional study Elsevier Early breast cancer Elsevier Trastuzumab Elsevier Sub-cutaneous injection Elsevier Safety profile |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
l u lu a s as j m f jmf a l al d s ds f d fd n c nc s p sp y b yb |
| hierarchy_parent_title |
The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study |
| hierarchy_parent_id |
ELV004843835 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV004843835 |
| title |
Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study |
| ctrlnum |
(DE-627)ELV049299751 (ELSEVIER)S0960-9776(19)30565-X |
| title_full |
Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study |
| author_sort |
Jacquin, Jean-Philippe |
| journal |
The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study |
| journalStr |
The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
zzz |
| container_start_page |
1 |
| author_browse |
Jacquin, Jean-Philippe |
| container_volume |
49 |
| physical |
7 |
| class |
610 VZ 44.65 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Jacquin, Jean-Philippe |
| doi_str_mv |
10.1016/j.breast.2019.10.002 |
| dewey-full |
610 |
| title_sort |
safety profile of subcutaneous trastuzumab in patients with her2-positive early breast cancer: the french hermione non-interventional prospective study |
| title_auth |
Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study |
| abstract |
HERmione study was conducted to assess, in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC), the safety profile of subcutaneous (SC) formulation of trastuzumab in real-life in France. |
| abstractGer |
HERmione study was conducted to assess, in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC), the safety profile of subcutaneous (SC) formulation of trastuzumab in real-life in France. |
| abstract_unstemmed |
HERmione study was conducted to assess, in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC), the safety profile of subcutaneous (SC) formulation of trastuzumab in real-life in France. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study |
| url |
https://doi.org/10.1016/j.breast.2019.10.002 |
| remote_bool |
true |
| author2 |
Uwer, Lionel Savignoni, Alexia Ferrero, Jean-Marc Lortholary, Alain Solub, David Delaporte, Flore Chalabi, Nassera Pibre, Sophie Belkacemi, Yazid |
| author2Str |
Uwer, Lionel Savignoni, Alexia Ferrero, Jean-Marc Lortholary, Alain Solub, David Delaporte, Flore Chalabi, Nassera Pibre, Sophie Belkacemi, Yazid |
| ppnlink |
ELV004843835 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.breast.2019.10.002 |
| up_date |
2024-07-06T21:11:22.613Z |
| _version_ |
1803865589141209088 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV049299751</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624153350.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200518s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.breast.2019.10.002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001071.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV049299751</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0960-9776(19)30565-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.65</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Jacquin, Jean-Philippe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">HERmione study was conducted to assess, in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC), the safety profile of subcutaneous (SC) formulation of trastuzumab in real-life in France.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HER2-Positive</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Prospective non-interventional study</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Early breast cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Trastuzumab</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sub-cutaneous injection</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Safety profile</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Uwer, Lionel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Savignoni, Alexia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ferrero, Jean-Marc</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lortholary, Alain</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Solub, David</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Delaporte, Flore</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chalabi, Nassera</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pibre, Sophie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Belkacemi, Yazid</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Yang, Lin ELSEVIER</subfield><subfield code="t">The clinical outcomes of endovenous microwave and laser ablation for varicose veins: A prospective study</subfield><subfield code="d">2020</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV004843835</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:49</subfield><subfield code="g">year:2020</subfield><subfield code="g">pages:1-7</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.breast.2019.10.002</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.65</subfield><subfield code="j">Chirurgie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">49</subfield><subfield code="j">2020</subfield><subfield code="h">1-7</subfield><subfield code="g">7</subfield></datafield></record></collection>
|
| score |
7.3986073 |